What question did this study set out to answer?

Identify and characterize early cancer progenitor/stem cell populations in prostate cancer and evaluate their genomic relevance to clinical outcomes.

February 1, 2008British Journal of CancerOpen Access

CD44+CD24− prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis

View Full Paper

Ask AI

Bookmark

Authors

EHElaine M. HurtAstraZeneca (Netherlands)BKBrian T. KawasakiFrederick National Laboratory for Cancer Research GKGeorge J. KlarmannUniformed Services University of the Health Sciences

Discussion

Member takes

Implication

Preclinical study demonstrates tumor-initiating capacity and poor-prognosis gene signatures in CD44+CD24- prostate stem cells, suggesting a viable target for therapeutic development.

Key Points

Identify and characterize early cancer progenitor/stem cell populations in prostate cancer and evaluate their genomic relevance to clinical outcomes.
Isolated CD44+CD24- cells from prostate cancer models using flow cytometry.
Evaluated clonogenic capacity in soft agar and sphere-forming capability in serum-replacement media with and without serum addition.
Assessed in vivo tumorigenicity by injecting as few as 100 cells into NOD/SCID mice and evaluated associated gene expression profiles.
Injections of as few as 100 CD44+CD24- cells successfully generated tumors in NOD/SCID mice, alongside robust colony formation in soft agar.
CD44+CD24- cells demonstrated elevated expression of stem cell maintenance genes BMI-1 and Oct-3/4, which altered toward a differentiated state upon serum exposure.
Gene expression signatures identified in CD44+CD24- cells directly correlated with poor overall survival in prostate cancer patients.

Cite This Study

Hurt et al. (2008) studied this question.

synapsesocial.com/papers/69e0818ad4cf97f1f4c11dc7 https://doi.org/10.1038/sj.bjc.6604242

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study demonstrates tumor-initiating capacity and poor-prognosis gene signatures in CD44+CD24- prostate stem cells, suggesting a viable target for therapeutic development.

CD44+CD24− prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis

Discussion

Member takes

Implication

Key Points

Cite This Study

CD44+CD24− prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider